



Assessment of Potential Nutraceuticals for Cancer Treatment Through Computational Method

Asad Ali*

College of Electronics and information Engineering, Shenzhen University, China

***Corresponding author:** College of Electronics and information Engineering, Shenzhen University, China**Received Date:** October 20, 2025**Published Date:** April 07, 2026

Abstract

Nutraceuticals such as curcumin, resveratrol, and epigallocatechin gallate (EGCG) have emerged as promising bioactive compounds with anticancer potential through the modulation of molecular signaling pathways. Recent advances in computational biology, particularly molecular docking and virtual screening, have accelerated the discovery of nutraceutical-protein interactions that underlie therapeutic efficacy. This summarizes key computational strategies focusing on AutoDock Vina for assessing the binding affinity and structural complementarity of nutraceuticals against major oncogenic targets, and outlines current challenges in translating in silico results into clinically meaningful interventions.

Keywords: Nutraceuticals; Cancer; Molecular Docking; AutoDock Vina; Computational Biology

Introduction

Cancer remains one of the leading causes of mortality worldwide, necessitating the continuous search for safer and more effective therapeutic agents. In this context, nutraceuticals naturally occurring dietary compounds with pharmacological activity offer a viable complementary approach to conventional chemotherapy. Several studies have highlighted that compounds such as curcumin, EGCG, quercetin, and lycopene exert antiproliferative, pro-apoptotic, and anti-angiogenic effects by modulating signaling cascades including PI3K/AKT, NF- κ B, and Wnt/ β -catenin [1–3]. Despite strong experimental evidence, the molecular basis of their selectivity and affinity toward cancer related proteins remains incompletely understood. Computational docking has therefore become an indispensable tool for visualizing and quantifying these interactions at the atomic level Figure 1.

Computational Methods and AutoDock Vina Framework

Molecular docking allows the prediction of the most energetically favorable orientation of a ligand within a target binding pocket, estimating the binding free energy and identifying key stabilizing interactions. AutoDock Vina, developed by Trott and Olson [4], is one of the most widely used open-source engines due to its balance between computational efficiency and prediction accuracy. The docking process generally begins with ligand and receptor preparation: three-dimensional structures of nutraceuticals are optimized and protonated at physiological pH, while crystallographic protein structures retrieved from the Protein Data Bank are refined by removing water molecules and adding polar hydrogens. Search grids are defined to encompass

the active site, followed by automated exploration of binding poses using stochastic optimization algorithms. The binding affinities,

expressed in kcal/mol, provide a comparative measure of interaction strength and complement experimental prioritization.




Figure 1: Computational pipeline for nutraceutical assessment using molecular docking and AutoDock Vina.




Figure 2: Representative docking poses showing (A) Curcumin binding to β -catenin and (B) EGCG interaction within VEGF receptor active site. Hydrogen bonds are highlighted in yellow.

AutoDock Vina 1.2.0 introduced expanded scoring functions, flexible residue handling, and Python bindings that facilitate high-throughput virtual screening [5]. For reproducibility, best practices include multiple docking runs with varied random seeds, pose clustering within an RMSD threshold of 2 Å, and redocking of co-crystallized ligands to validate pocket selection. Combining Vina

with deep-learning-assisted rescoring engines such as GNINA can further improve binding-pose discrimination [6]. The integration of ADMET prediction and molecular dynamics simulation provides additional refinement to evaluate pharmacokinetic feasibility Figure 2.

Applications to Nutraceuticals in Cancer Research

Curcumin, a polyphenolic compound derived from *Curcuma longa*, has been computationally and experimentally validated as an inhibitor of multiple oncogenic pathways. Docking studies have demonstrated favorable binding (-6 to -9 kcal/mol) toward kinases and transcriptional regulators such as EGFR, BCL-2, and β -catenin, supporting its role in apoptosis induction and metastasis suppression [2, 7]. Similarly, EGCG, the major catechin in green tea, exhibits high binding affinity with VEGF receptors, matrix metalloproteinases, and topoisomerase, rationalizing its

anti-angiogenic and cytostatic effects [3, 8]. Other nutraceuticals such as resveratrol and quercetin also show multi-target binding patterns that correlate with antioxidant and anti-inflammatory properties. While docking energies and hydrogen-bond patterns provide mechanistic hypotheses, bioavailability and metabolic stability remain key bottlenecks. Many nutraceuticals suffer from poor aqueous solubility and rapid metabolism; thus, the design of nanoparticle or phytosome based formulations has become a parallel computational target. In silico docking can also assess drug-excipient interactions, ensuring the retention of pharmacophoric integrity in delivery systems [9, 10] Figure 3.




Figure 3: Nutraceutical sources and their corresponding molecular pathways implicated in anticancer activity.

Challenges and Future Perspectives

Although docking offers rapid screening and hypothesis generation, the accuracy of predicted affinities depends on the scoring function and the quality of the receptor structure. Flexible binding pockets, allosteric sites, and solvent effects are often simplified in classical docking, potentially leading to false positives or overestimated affinities. Moreover, nutraceuticals typically exert polypharmacological effects that challenge single-target assumptions. Future computational pipelines should integrate molecular dynamics, quantum mechanics/molecular mechanics (QM/MM) refinement, and network pharmacology approaches to capture the systemic impact of nutraceuticals on interconnected pathways. The increasing incorporation of machine-learning-based scoring and large-scale datasets is expected to further enhance predictive reliability and guide experimental validation [11].

Conclusion

Computational methods such as molecular docking and AutoDock Vina have transformed the early-stage evaluation of nutraceuticals for cancer therapy. By revealing the structural determinants of binding and providing rapid screening capability, these tools bridge the gap between traditional natural product

research and precision oncology. However, successful translation from virtual hits to clinical outcomes will require multidisciplinary integration of computational chemistry, formulation science, and experimental pharmacology. Continued methodological advances promise to accelerate the rational design of nutraceutical-based anticancer therapeutics.

References

1. P C Agu C A Afiukwa, O U Orji, E M Ezech, I H Ofoke, et al. (2023) Molecular docking as a tool for the discovery of nutraceutical targets. *Scientific Reports* 13(1): 14053.
2. Shadiya Fawzul Ameer, Muna Yusuf Mohamed, Qubaa Ahmed Elzubair, Elham Abdullatif M Sharif, Wisam Nabeel Ibrahim (2024) Curcumin as a novel therapeutic candidate for cancer. *Frontiers in Oncology* 14.
3. M Kciuk, Manzar Alam, Nemat Ali, Summya Rashid, Pola Głowacka, et al. (2023) Epigallocatechin-3-gallate: therapeutic potential in cancer. *Cancers* 15(13): 3387.
4. Oleg Trott and Arthur J Olson (2010) Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of Computational Chemistry*, 31(2): 455-461.
5. Jakob Eberhardt, Diogo Santos-Martins, Andreas Tillack, and Stefano Forli (2021) Autodock vina 1.2.0: new docking methods, expanded force field, and python bindings. *Journal of Chemical Information and Modeling* 61(8): 3891-3898.

6. Alexander T McNutt et al. (2021) Gnina 1.0: molecular docking with deep learning. *Journal of Cheminformatics* 13(1): 43.
7. V Zoi, Vasiliki Galani, Georgios D Lianos, Spyridon Voulgaris, Athanasios P Kyritsis, et al. (2021) The role of curcumin in cancer treatment. *Cancers* 13(16): 3927.
8. W Sun, Yizhuang Yang, Cuiyun Wang, Mengmeng Liu, Jianhua Wang, et al. (2024) Egcg at the nanoscale: a new strategy to overcome delivery challenges. *Pharmaceutical Biology* 62(1): e2406779.
9. M Talebi, Kimia Shahbazi, Mohammad Sedigh, Marziyeh Akbari, Rouzbeh Almasi Ghale, et al. (2025) Phytosomes: a promising nanocarrier system for enhanced delivery of phytoconstituents. *Journal of Herbal Nanotechnology* 5(2).
10. M Singla et al. (2023) Unlocking the power of nanomedicine for phytoconstituents in cancer. *Trends in Pharmacological Sciences*.
11. J Lee (2025) Beyond rigid docking: deep learning approaches for fully flexible docking. *Briefings in Bioinformatics*, 26(3): bbaf454.